A Ray Of Hope In Treating Tuberculosis
Tuberculosis is almost an unknown disease for new generations of the developed countries since the disease is relegated to the poorest areas of our planet. However, despite the progress that has been made in preventing, still present in countries like ours where there are more than 5,000 cases each year are registered, according to the Spanish Society of Pneumology and Thoracic Surgery (Separ). Its poor visibility is responsible for the lack of investment in research and 90 years have passed until it has given new hope. Its name has achieved MTBVAC and to Dr. Carlos Martín, Mycobacterial group at the University of Zaragoza, after ten years trying to isolate bacteria of human origin. A global milestone in the search for preventive treatment for this condition is being searched because all vaccines in the investigation are of animal origin. ‘We are facing a serious problem being solved,’ he said during Carmen Vela, Secretary of State for Research, Development and Innovation.
The hope in Spain is the only alternative to widespread vaccine worldwide, BCG, of bovine origin. Find the antidote to prevent the oral transmission where the disease is mainly found, “is the main mission of this vaccine that has just concluded its Phase I’ explained Martin. 36 volunteers participated in the study that began in January 2013 at the University Hospital of Vaud in Switzerland and has funding of European funds and the Bill and Melinda Gates Foundation. The volunteer patients were injected with the dose of 0.1 milliliters and so far, none has developed the disease, but until the first quarter of 2014 will not be the final data.
‘The economic cost of tuberculosis in developed countries is six billion euros and to prevent it makes a more effective vaccine,’ insisted Jelle Thole, director of the European Initiative for TB (TBVI). Besides the European support behind a laboratory, it is also developing Spanish, Biofabri, which, when exceeded all phases wants to ‘produce the vaccine for everyone in Spain’, says spokesman Eugenia Bridges. It is too early to know when to hit the drugstores, but Thole risks: ‘If all goes well, we hope to have in ten years and its cost is very low.’ The crisis is helping the spread of TB as alert Joan Caila, Tuberculosis Group Separ, ‘in a few years, we may see a rise in countries that are faring worse.’
For more: http://www.reviewlization.com/